Grufity logoGrufity logo

Eli Lilly and Co Stock Research

LLY

329.53USD+0.06(+0.02%)Market Closed

Market Summary

USD329.53+0.06
Market Closed
0.02%

LLY Alerts

LLY Stock Price

LLY RSI Chart

LLY Valuation

Market Cap

296.8B

Price/Earnings (Trailing)

47.53

Price/Sales (Trailing)

10.4

EV/EBITDA

35.39

Price/Free Cashflow

41.9

LLY Price/Sales (Trailing)

LLY Profitability

EBT Margin

23.85%

Return on Equity

58.64%

Return on Assets

12.62%

Free Cashflow Yield

2.39%

LLY Fundamentals

LLY Revenue

Revenue (TTM)

28.5B

Revenue Y/Y

-8.73%

Revenue Q/Q

5.19%

LLY Earnings

Earnings (TTM)

6.2B

Earnings Y/Y

12.26%

Earnings Q/Q

33.48%

Price Action

52 Week Range

273.86384.44
(Low)(High)

Last 7 days

5.4%

Last 30 days

-5.7%

Last 90 days

-8.5%

Trailing 12 Months

20.7%

LLY Financial Health

Current Ratio

1.05

LLY Investor Care

Dividend Yield

1.24%

Dividend/Share (TTM)

4.07

Buy Backs (1Y)

0.66%

Diluted EPS (TTM)

6.9

Peers (Alternatives to Eli Lilly and)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
JNJ
404.8B
94.9B
 -5.16% -10.64%
22.56
4.26
 1.25% -14.07%
LLY
296.8B
28.5B
 -5.67% 20.74%
47.53
10.4
 0.79% 11.88%
MRK
272.8B
59.3B
 -1.75% 40.02%
17.88
4.63
 21.72% 11.27%
PFE
226.4B
100.3B
 -8.43% -20.95%
7.22
2.26
 23.43% 42.74%
BMY
142.7B
46.2B
 -7.78% -1.12%
22.55
3.09
 -0.49% -9.54%
MID-CAP
PRGO
4.8B
4.5B
 -0.20% -5.41%
-34.17
1.08
 7.56% -104.06%
RETA
3.3B
2.2M
 105.10% 171.03%
-10.52
1.5K
 -80.71% -4.88%
SMALL-CAP
SUPN
1.9B
667.2M
 -9.96% 17.66%
31.57
2.87
 15.09% 13.64%
TLRY
1.6B
602.5M
 -17.77% -52.80%
-2.74
2.63
 18.18% -18.59%
CGC
991.7M
478.9M
 -11.35% -65.42%
-0.32
2.07
 -31.50% -634.70%
INVA
792.9M
285.2M
 -7.22% -37.95%
3.6
2.78
 -27.21% -40.28%
CRON
768.8M
114.5M
 -15.28% -37.42%
-4.56
6.72
 27.90% 57.40%
ACRS
541.5M
29.8M
 -40.95% -47.43%
-6.23
18.2
 340.05% 4.35%
OCUL
400.7M
51.5M
 -2.49% -0.39%
-5.64
7.78
 18.32% -984.05%
ENDP
94.1M
2.3B
 -43.99% -88.43%
-0.03
0.04
 -22.53% -376.66%

Financials for Eli Lilly and

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-2.4%28,54129,24029,07129,32328,318
  S&GA Expenses0.8%6,4406,3896,3536,4146,432
  R&D Expenses1.4%7,1917,0936,9966,8696,931
EBITDA2.3%8,3298,1437,8428,366-
EBITDA Margin4.8%0.29*0.28*0.27*0.29*-
Earnings Before Taxes3.9%6,8066,5506,2306,7336,156
EBT Margin6.5%0.24*0.22*0.21*0.23*-
Net Income3.5%6,2456,0335,6926,1295,582
Net Income Margin6.0%0.22*0.21*0.20*0.21*-
Free Cahsflow-7.5%7,0847,6617,1088,063-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets4.3%49,49047,46247,06446,91948,806
  Current Assets2.2%18,03517,64017,11516,96518,452
    Cash Equivalents-21.0%2,0672,6172,6232,4593,819
  Inventory12.5%4,3103,8313,8993,8933,886
  Net PPE8.9%10,1449,3119,1289,1038,985
  Goodwill4.7%4,0733,8923,8923,8923,892
  Current Liabilities9.5%17,13815,65315,62113,38615,053
    LT Debt, Non Current4.2%14,73814,14414,69215,15315,346
Shareholder's Equity5.8%10,65010,0708,5459,3318,979
  Retained Earnings0.4%10,04310,0078,5569,3698,959
  Additional Paid-In Capital1.4%6,9216,8296,7466,6566,833
Accumulated Depreciation-0.5%10,07410,12010,1389,977-
Shares Outstanding0.0%901900904--
Minority Interest31.1%12696.00115131176
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-7.5%7,0847,6617,1088,0637,261
  Share Based Compensation5.0%371354359358343
Cashflow From Investing-17.3%-3,261-2,780-2,473-2,492-2,762
Cashflow From Financing6.6%-5,406-5,791-4,991-5,951-4,131
  Dividend Payments3.2%3,5363,4253,3133,1983,087
  Buy Backs-33.3%1,5002,2502,2502,7501,250

Risks for LLY

What is the probability of a big loss on LLY?

14.2%

Probability that Eli Lilly and stock will be more than 20% underwater in next one year

0%

Probability that Eli Lilly and stock will be more than 30% underwater in next one year.

0%

Probability that Eli Lilly and stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does LLY drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Eli Lilly and was unfortunately bought at previous high price.

Drawdowns

Returns for LLY

Cumulative Returns on LLY

22.4%

10-Year Cumulative Returns

26.7%

7-Year Cumulative Returns

34.9%

5-Year Cumulative Returns

35.2%

3-Year Cumulative Returns

What are the long-term rolling returns for LLY?

FIve years rolling returns for Eli Lilly and.

Annualized Returns

Which funds bought or sold LLY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
added
11.47
3,006,020
14,514,000
 0.41%
2023-03-13
Claro Advisors LLC
added
16.86
116,233
479,233
 0.16%
2023-03-10
MATHER GROUP, LLC.
added
12.78
410,849
1,897,850
 0.04%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
added
2.62
33,979,800
245,004,000
 0.27%
2023-03-08
SHEETS SMITH WEALTH MANAGEMENT
reduced
-4.94
59,029
844,029
 0.13%
2023-03-08
Capital Asset Advisory Services LLC
added
21.72
467,373
1,694,370
 0.14%
2023-03-07
Great Lakes Retirement, Inc.
new
-
1,924,410
1,924,410
 0.49%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-28.89
-47,100,000
193,928,000
 0.98%
2023-03-06
BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL
reduced
-0.51
681,870
6,105,870
 2.32%
2023-03-06
Aldebaran Financial Inc.
reduced
-10.76
1,376
379,376
 0.41%

1–10 of 47

Latest Funds Activity

Are funds buying LLY calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own LLY
No. of Funds

LLY Alerts

Eli Lilly and News

MarketBeat

City State Bank Has $1.43 Million Holdings in Eli Lilly and Company ....

MarketBeat,
18 hours ago

Nasdaq

European shares rise as banking turmoil eases; set to end volatile ....

Nasdaq,
2 days ago

Forbes

Caterpillar Stock Appears To Be A Better Pick Over This Pharmaceuticals Giant.

Forbes,
3 days ago

InvestorsObserver

Is Eli Lilly And Co (LLY) Stock at the Top of the Drug Manufacturers - General Industry?.

InvestorsObserver,
5 days ago

Reuters

Novo Nordisk to slash US insulin prices, following move by Eli Lilly.

Reuters,
5 days ago

Seeking Alpha

LLY stock upgraded at Wells Fargo citing opportunity after weakness ....

Seeking Alpha,
6 days ago

Nasdaq

Guru Fundamental Report for LLY.

Nasdaq,
6 days ago

InvestorsObserver

Is Eli Lilly And Co (LLY) Stock About to Get Hot Friday?.

InvestorsObserver,
9 days ago

StockNews.com

LLY: 5 Best Pharma Stocks to Buy Right Now.

StockNews.com,
10 days ago

Investors | Eli Lilly and Company

Lilly Provides Update on A4 Study of Solanezumab for Preclinical ....

Investors | Eli Lilly and Company,
12 days ago

Zacks Investment Research

Lilly's (LLY) Verzenio Gets FDA Nod for Expanded Breast Cancer.

Zacks Investment Research,
13 days ago

Investors | Eli Lilly and Company

Intensive education at clinics about multidisciplinary care improved ....

Investors | Eli Lilly and Company,
14 days ago

MarketBeat

Livforsakringsbolaget Skandia Omsesidigt Has $8.90 Million ....

MarketBeat,
17 days ago

Seeking Alpha

Eli Lilly wins additional breast cancer indication for Verzenio (NYSE ....

Seeking Alpha,
17 days ago

Seeking Alpha

Eli Lilly licenses non opioid pain med for $40M upfront (NYSE:LLY).

Seeking Alpha,
18 days ago

Seeking Alpha

Eli Lilly slashes insulin prices by 70%, places $35 monthly out-of ....

Seeking Alpha,
19 days ago

Schedule 13G FIlings of Eli Lilly and

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
7.73%
73,429,863
SC 13G/A
Feb 01, 2023
blackrock inc.
6.9%
65,467,793
SC 13G/A
Jan 25, 2023
lilly endowment inc
10.83%
102,948,810
SC 13G/A
Feb 11, 2022
pnc financial services group, inc.
5.42%
51,888,455
SC 13G/A
Feb 09, 2022
vanguard group inc
7.24%
69,261,754
SC 13G/A
Feb 08, 2022
blackrock inc.
6.7%
63,877,023
SC 13G/A
Jan 27, 2022
lilly endowment inc
11.23%
107,463,810
SC 13G/A
Feb 12, 2021
pnc financial services group, inc.
5.44%
52,012,151
SC 13G/A
Feb 10, 2021
vanguard group inc
7.18%
68,661,494
SC 13G/A
Jan 29, 2021
blackrock inc.
6.1%
58,811,768
SC 13G/A

LLY Fair Value

Eli Lilly and fair value in different scenarios

The table shows the Fair Value estimates for Eli Lilly and for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

70.95

-78.47%

84.47

-74.37%

127.92

-61.18%

174.93

-46.92%

222.33

-32.53%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Eli Lilly and Fair Value Estimates

Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Eli Lilly and

View All Filings
Date Filed Form Type Document
Mar 13, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 01, 2023
4
Insider Trading
Feb 24, 2023
PRE 14A
PRE 14A
Feb 24, 2023
8-K
Current Report
Feb 24, 2023
424B2
Prospectus Filed
Feb 23, 2023
424B2
Prospectus Filed

Latest Insider Trading transactions for LLY

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-10
Weems Alonzo
sold
-318,850
318
-1,000
evp, erm & ceco
2023-03-01
Weems Alonzo
acquired
-
-
1,779
evp, erm & ceco
2023-03-01
Hernandez Edgardo
acquired
-
-
1,890
evp & pres., mfg. operations
2023-03-01
Dozier Eric
sold (taxes)
-222,211
311
-714
evp, hr & diversity
2023-03-01
Weems Alonzo
sold (taxes)
-246,797
311
-793
evp, erm & ceco
2023-03-01
Dozier Eric
acquired
-
-
1,602
evp, hr & diversity
2023-03-01
Hernandez Edgardo
sold (taxes)
-262,358
311
-843
evp & pres., mfg. operations
2023-02-27
Zakrowski Donald A
sold
-193,482
322
-600
svp, finance, & cao
2023-02-21
Hedley Mary Lynne
acquired
9,825
327
30.00
-
2023-02-21
JOHNSON KIMBERLY H
acquired
9,825
327
30.00
-

1–10 of 50

About Eli Lilly and

David A. Ricks
www.lilly.com
35000
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

LLY Income Statement

2022-12-31
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]   
Revenue (Note 2)$ 28,541.4$ 28,318.4$ 24,539.8
Costs, expenses, and other:   
Cost of sales6,629.87,312.85,483.3
Research and development7,190.86,930.75,976.3
Marketing, selling, and administrative6,440.46,431.66,121.2
Acquired in-process research and development and development milestones (Note 3)908.5970.1769.8
Asset impairment, restructuring, and other special charges (Note 5)244.6316.1131.2
Other—net, (income) expense (Note 18)320.9201.6(1,171.9)
Costs, expenses, and other21,735.022,162.917,309.9
Income before income taxes6,806.46,155.57,229.9
Income taxes (Note 14)561.6573.81,036.2
Net income$ 6,244.8$ 5,581.7$ 6,193.7
Earnings per share:   
Basic (in dollars per share)$ 6.93$ 6.15$ 6.82
Diluted (in dollars per share)$ 6.90$ 6.12$ 6.79
Shares used in calculation of earnings per share:   
Basic (in shares)901,736906,963907,634
Diluted (in shares)904,619911,681912,505

LLY Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Current Assets  
Cash and cash equivalents (Note 7)$ 2,067.0$ 3,818.5
Short-term investments (Note 7)144.890.1
Accounts receivable, net of allowances of $16.0 (2022) and $22.5 (2021)6,896.06,672.8
Other receivables1,662.91,454.4
Inventories (Note 6)4,309.73,886.0
Prepaid expenses and other current assets2,954.12,530.6
Total current assets18,034.518,452.4
Investments (Note 7)2,901.83,212.6
Goodwill (Note 8)4,073.03,892.0
Other intangibles, net (Note 8)7,206.67,691.9
Deferred tax assets (Note 14)2,792.92,489.3
Property and equipment, net (Note 9)10,144.08,985.1
Other noncurrent assets4,337.04,082.7
Total assets49,489.848,806.0
Current Liabilities  
Short-term borrowings and current maturities of long-term debt (Note 11)1,501.11,538.3
Accounts payable1,930.61,670.6
Employee compensation1,059.8958.1
Sales rebates and discounts8,784.16,845.8
Dividends payable1,017.2885.5
Income taxes payable (Note 14)475.1126.9
Other current liabilities2,370.33,027.5
Total current liabilities17,138.215,052.7
Other Liabilities  
Long-term debt (Note 11)14,737.515,346.4
Accrued retirement benefits (Note 15)1,305.11,954.1
Long-term income taxes payable (Note 14)3,709.63,920.0
Deferred tax liabilities (Note 14)87.31,733.7
Other noncurrent liabilities1,736.71,644.3
Total other liabilities21,576.224,598.5
Commitments and Contingencies (Note 16)
Eli Lilly and Company Shareholders' Equity (Notes 12 and 13)  
Common stock—no par value Authorized shares: 3,200,000 Issued shares: 950,632 (2022) and 954,116 (2021)594.1596.3
Additional paid-in capital6,921.46,833.4
Retained earnings10,042.68,958.5
Employee benefit trust(3,013.2)(3,013.2)
Accumulated other comprehensive loss (Note 17)(3,844.6)(4,343.1)
Cost of common stock in treasury(50.5)(52.7)
Total Eli Lilly and Company shareholders' equity10,649.88,979.2
Noncontrolling interests125.6175.6
Total equity10,775.49,154.8
Total liabilities and equity$ 49,489.8$ 48,806.0